Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI67
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome40
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis36
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis34
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment29
Cardio-rheumatology: integrated care and the opportunities for personalized medicine26
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients26
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis24
Serious infection risk in older adults with RA receiving biologic or targeted synthetic DMARDs: the role of age at disease onset24
Forced vital capacity as a survival predictor in systemic sclerosis-associated pulmonary hypertension24
From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis19
The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case–control study18
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study17
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs16
Plain language summary: gout remission with pegloticase15
0.050091028213501